查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1986861

孤儿药市场规模、份额、趋势和预测：按药物类型、疾病类型、研发阶段、畅销药物、分销管道和地区划分，2026-2034年

Orphan Drugs Market Size, Share, Trends and Forecast by Drug Type, Disease Type, Phase, Top Selling Drugs, Distribution Channel, and Region, 2026-2034
出版日期: | 出版商: IMARC | 英文 144 Pages | 商品交期: 2-3个工作天内

价格

2025年全球孤儿药市场规模为2,610亿美元。展望未来，IMARC集团预测，该市场将以9.47%的复合年增长率从2026年增长至2034年，到2034年达到5,892亿美元。目前，北美是该市场的主要驱动力，占35.5%的市场。孤儿药市场份额的扩大得益于人​​们日益认识到罕见疾病是一项重大的公共卫生挑战，基因组学、生物技术和精准医疗的进步，以及国内外卫生监管机构出台的有利法规结构。

孤儿药市场的发展主要得益于有利的法规环境和政府为促进罕见疾病治疗方法研发所提供的奖励。监管机构提供的奖励包括市场独占权、税额扣抵、费用减免和加快核准流程。这些奖励显着降低了製药公司的财务风险，并促进了特定治疗领域的创新。另一个主要驱动因素是全球罕见病患疾病率的不断上升，以及人们对罕见疾病认知的提高和诊断技术的进步。基因组学和个人化医疗的进步提高了罕见遗传疾病的检测和标靶化，从而推动了对孤儿药的需求。

美国孤儿药市场受多种因素驱动。罕见病患疾病率的不断上升影响着大量美国人，凸显了对特药日益增长的需求。先进的基因筛检和诊断技术能够早期、准确地识别罕见疾病，从而扩大了目标患者群体。此外，孤儿病组织和病患小组的有效倡导提高了公众对孤儿药的认知度、资金筹措和患者获取途径。美国医疗保健体系中孤儿药的高定价潜力以及积极的报销政策也促进了市场成长。由于替代治疗方法有限以及所治疗疾病的严重，孤儿药往往价格昂贵。 2025 年，美国食品药物管理局(FDA) 授予 ilzabrutinib 孤儿药资格，这是一种处于实验阶段的新型、先进的、口服可逆的布鲁蛋白酪氨酸激酶(BTK) 抑製剂，用于治疗两种罕见疾病，包括高热自体免疫溶血性贫血 (wAIHA) 和 IgG4 相关疾病 (IgG4-RD)。

孤儿药市场趋势：

罕见病患疾病率和公众意识的提高

人们日益认识到罕见疾病是一项重大的公共卫生挑战，这正在推动市场成长。据估计，到2024年，全球将有约3亿人患有罕见疾病。除了盛行率上升之外，流行病学研究和病患登记系统的改进也让我们对这些疾病有了更全面的了解。倡导团体、非营利组织和宣传宣传活动在教育医疗专业人员、政策制定者和公众方面也发挥着至关重要的作用。公众意识的提高促进了早期诊断和疾病管理的改善，同时也增加了对新治疗方法的需求。各国政府和私人企业正在加大对罕见疾病研究的投入，而资料共用的加强也提高了开发平臺效率。

基因组学和精准医学的进展

基因组学、生物技术和精准医学领域的科技进步正在迅速改变罕见疾病的诊断和治疗，从而改善孤儿药市场的前景。基因测序、生物资讯学和个人化医疗调查方法正在促进更精准的诊断和个人化治疗方案的製定，尤其适用于罕见且复杂的遗传性疾病。这些技术透过将药物作用机制与个别遗传标记连结起来，缩短了药物研发週期，提高了标靶治疗的成功率。此外，伴随诊断的出现正在改善患者筛选和监测，从而增强治疗的有效性和安全性。生物製药公司正越来越多地利用这些技术，开发针对少数但需求未被满足的患者群体的新型生技药品、基因疗法和基于核糖核酸（RNA）的治疗方法。 IMARC集团预测，到2033年，伴随诊断市场规模将达223亿美元。

有利的法规结构和政府奖励

国内外卫生机构提供的有利法规结构正在推动孤儿药市场的成长。世界各国提供各种奖励，鼓励製药公司投资罕见疾病治疗。这些奖励通常包括市场独占权、临床研究税额扣抵、监管费用豁免、快速核准和津贴。这些措施显着降低了孤儿药研发的财务门槛，因为孤儿药针对的是少数病患群体，商业性价值较低。这些监管支持增强了企业的信心，为开发和销售针对弱势患者群体的未满足需求的治疗方法创造了更稳定可靠的环境，并维持了市场的长期成长。此外，各国政府正为罕见疾病管理拨出专案预算，这进一步刺激了对孤儿药的需求。例如，印度政府根据自然资源保护委员会（NRDC）的提案，宣布计划设立国家罕见疾病基金（NFRD），目前正在等待卫生和家庭福利部（MoHFW）的等候核准，併计划在2024-25和2025-26财年累计97.4亿卢比。预计在2026-27和2027-28财年也将累计类似或略多的款项。

目录

第一章：序言

第二章：调查方法

  • 调查目的
  • 相关利益者
  • 数据来源
    • 主要讯息
    • 二手资讯
  • 市场估值
    • 自下而上的方法
    • 自上而下的方法
  • 调查方法

第三章执行摘要

第四章：引言

第五章：全球孤儿药市场

  • 市场概览
  • 市场表现
  • 新冠疫情的影响
  • 市场预测

第六章 市场区隔：依药物类型划分

  • 生物製药
  • 非生物製药

第七章 市场区隔：依疾病分类

  • 肿瘤学
  • 血液学
  • 神经病学
  • 循环系统
  • 其他的

第八章 市场区隔：依阶段划分

  • 第一阶段
  • 第二阶段
  • 第三阶段
  • 第四阶段

第九章 市场区隔：依畅销药物划分

  • Revlimid
  • Rituxan
  • 科帕松
  • 奥普迪沃
  • Keytruda
  • Imbruvica
  • Avonex
  • 森西珀
  • Soliris
  • 其他的

第十章 市场区隔：依分销通路划分

  • 医院药房
  • 零售药房
  • 网路商店
  • 其他的

第十一章 市场区隔：按地区划分

  • 北美洲
    • 我们
    • 加拿大
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲

第十二章 SWOT 分析

第十三章：价值链分析

第十四章：波特五力分析

第十五章：价格分析

第十六章 竞争格局

  • 市场结构
  • 主要企业
  • 主要企业简介
    • Alexion Pharmaceuticals Inc.
    • Amgen Inc.
    • AstraZeneca
    • Bayer AG
    • Daiichi Sankyo Company Limited
    • Genentech USA, Inc（F. Hoffmann-La Roche AG）
    • GSK plc
    • Johnson & Johnson
    • Merck & Co., Inc.
    • Novartis Pharmaceuticals Corporation
    • Pfizer Inc.
    • Sanofi SA
    • Takeda Pharmaceuticals USA, Inc
Product Code: SR112026A2382

The global orphan drugs market size was valued at USD 261.0 Billion in 2025. Looking forward, IMARC Group estimates the market to reach USD 589.2 Billion by 2034, exhibiting a CAGR of 9.47% from 2026-2034. North America currently dominates the market with 35.5% of the market share. The orphan drugs market share is expanding, driven by the increasing knowledge of rare diseases as a major public health issue, technological advancements in genomics, biotech, and precision medicine, and favorable regulatory framework offered by different national and international health authorities.

The market for orphan drugs is largely driven by supportive regulatory environments and government incentives to foster the development of therapies for rare diseases. Regulators offer incentives such as market exclusivity, tax credits, lower fees, and accelerated approval procedures. These incentives greatly lower the cost of financial risk for pharmaceutical firms and stimulate innovation in specialized therapeutic areas. Another key driver is the increasing incidence of rare diseases worldwide, combined with increased awareness and enhanced diagnostic technology. Developments in genomics and personalized medicine are allowing for improved detection and targeting of rare genetic disorders, driving the demand for orphan drugs.

The orphan drugs market in the United States is driven by several factors. The growing incidence of rare diseases, impacting a huge number of Americans, highlights the expanding need for specialized medicines. Advanced genetic screening and diagnostic technologies are allowing for earlier and more precise identification of rare conditions, driving a larger addressable patient base. Additionally, effective advocacy by rare disease organizations and patient groups is enhancing awareness, funding, and patient access to orphan drugs. High price potential and positive reimbursement practices in the American healthcare infrastructure also favor expansion opportunities. Orphan drugs also tend to bear higher prices given scarce alternatives as well as due to the extremely serious nature of conditions they seek to treat. In 2025, the US Food and Drug Administration (FDA) has awarded orphan drug status to rilzabrutinib, an experimental, new, advanced, oral, reversible Bruton's tyrosine kinase (BTK) inhibitor, for two rare diseases, including warm autoimmune hemolytic anemia (wAIHA) and IgG4-related disease (IgG4-RD).

ORPHAN DRUGS MARKET TRENDS:

Increasing Prevalence and Awareness About Rare Diseases

The increasing knowledge of rare diseases as a major public health issue is driving the growth of the market. In 2024, it was estimated that approximately 300 million billion around world lived with rare diseases. Increasing prevalence rates, combined with enhanced epidemiological studies and patient registries, are illuminating the scope of these disorders. Greater awareness through advocate groups, non-profit organizations, and public campaigns has also been important in bringing education to healthcare providers, policymakers, and the general public. Greater awareness not only improves earlier diagnosis and disease management but also improves demand for novel therapies. Governments and private companies are committing more resources to rare disease research, and enhanced data sharing is moving the development pipeline more efficiently.

Advancements in Genomics and Precision Medicine

Technological advancements in genomics, biotech, and precision medicine are transforming the diagnosis and management of rare diseases at a strong pace offering a favorable orphan drugs market outlook. Genomic sequencing, bioinformatics, and personalized medicine methodologies are facilitating more accurate diagnosis and individualized treatment plans, especially for rare and complex genetic disorders. These technologies have compressed the drug discovery process and improved the success rate of targeted therapies by correlating drug mechanisms with individual genetic markers. In addition, the emergence of companion diagnostics enables improved patient selection and monitoring, which improves treatment efficacy and safety. Biopharmaceutical firms are increasingly using these technologies to create new biologics, gene therapies, and ribonucleic acid (RNA)-based treatments for small patient populations with high unmet medical needs. The IMARC Group predicts that the companion diagnostics market is expected to reach USD 22.3 Billion by 2033.

Favorable Regulatory Frameworks and Government Incentives

The favorable regulatory framework offered by different national and international health authorities is impelling the orphan drugs market growth. Various countries around the world provide a wide range of incentives designed to encourage pharmaceutical firms to invest in rare disease treatments. These incentives generally range from market exclusivity, clinical research tax credits, regulatory fees waiver, expedited approvals, and grant dollars. These encourage significantly the reductions of the money hurdles involved with the research and development of these orphan drugs with small target numbers and little commercial value. This regulatory encouragement builds confidence and generates a more stable and secure setting for firms to create and market therapies for unmet and vulnerable patient segments, sustaining long-term market growth. Governments are also allocating budgets for managing rare diseases, which is further driving the need for orphan drugs. For instance, Union of India announced its plan to establish a National Fund for Rare Diseases (NFRD) and provision for ₹974 crore for FYs 2024-25 and 2025-26 as suggested by NRDC awaiting MoHFW clearance. Similarly, or slightly greater, fund amount shall be provisioned for 2026-27 and 2027-28.

ORPHAN DRUGS INDUSTRY SEGMENTATION:

Analysis by Drug Type :

  • Biological
  • Non-Biological

Biological holds 65.8% of the market share. It represents the largest segment, chiefly because of their success in treating the underlying pathophysiologic mechanisms of orphan diseases. It is generally developed from living organisms and comprise monoclonal antibodies, gene therapies, recombinant proteins, and cell-based medicines. Its potential to provide targeted, disease-modifying actions renders them very well adapted to intricate and genetically influenced diseases. As biotechnology and genomics advance, biologics are being developed more for an increasingly broad range of rare conditions, such as specific cancers, immunodeficiencies, and metabolic diseases. Their growing presence in the market is facilitated by the robust pipeline of biologic orphan drugs, as well as by favorable regulatory mechanisms like fast-track approval and orphan designation. Moreover, the premium pricing and longer development cycles associated with biologics are often justified by their therapeutic value, especially in cases where treatment alternatives are limited or non-existent.

Analysis by Disease Type :

  • Oncology
  • Hematology
  • Neurology
  • Cardiovascular
  • Others

Oncology holds 36.6% of the market share. The oncology segment holds a dominant position in the orphan drugs space due to the prevalent incidence of uncommon cancers and the pressing demand for targeted therapy. Uncommon cancers, like particular forms of leukemia, sarcomas, and lymphomas, tend to have fewer or no viable treatments, fueling immense research and development efforts. Pharmaceutical firms are moving more and more towards these orphan oncology indications because of advantages provided under the orphan drug act, such as market protection and lower development expense. Molecular biological advancements and the use of immunotherapy have increasingly pushed the speed of development in personalized cancer care, such as monoclonal antibodies and checkpoint inhibitors. Also, the partnerships among academic institutions and biotech companies have resulted in the discovery of novel biomarkers and pathways for unusual cancer subtypes.

Analysis by Phase :

  • Phase I
  • Phase II
  • Phase III
  • Phase IV

Phase I of orphan drug development focuses on evaluating safety, dosage range, and pharmacokinetics in a small group of healthy volunteers or affected patients. This phase plays a critical role in laying the foundation for subsequent clinical trials. Although the patient population is typically small, which aligns with the nature of rare diseases, careful monitoring is required to assess tolerability and identify any adverse reactions.

Phase II trials for orphan drugs are designed to evaluate therapeutic efficacy and further assess safety in a larger cohort of patients who are affected by the rare disease under investigation. This phase is particularly crucial in the orphan drug landscape, as it provides initial evidence of the drug's clinical benefit, which can guide decision-making for Phase III trials.

Phase III is the most resource-intensive phase of orphan drug development, focused on confirming the drug's efficacy, monitoring side effects, and comparing its performance to existing treatments or placebos.

Phase IV, or post-marketing surveillance, focuses on monitoring the long-term safety, effectiveness, and overall impact of orphan drugs after they receive regulatory approval and enter the market.

Analysis by Top Selling Drugs :

  • Revlimid
  • Rituxan
  • Copaxone
  • Opdivo
  • Keytruda
  • Imbruvica
  • Avonex
  • Sensipar
  • Soliris
  • Other

Keytruda holds 15.7% of the market share. Keytruda (pembrolizumab) is one of the best-selling medicines, including in the orphan drugs market. It is a PD-1 inhibitor that has found widespread use in oncology, especially for rare cancers such as Merkel cell carcinoma and primary mediastinal large B-cell lymphoma. Keytruda's success in gaining orphan drug status in several indications reflects its therapeutic utility and effectiveness in the treatment of diseases with high unmet needs. Its extensive clinical value and positive results have made it a pillar of immunotherapy, with uses that tend to go beyond initial approval ranges through continued studies and trials. By providing a notable survival advantage in a number of uncommon oncological disorders, Keytruda has set the standard for precision medicine. Regulatory pressure and ongoing innovation in biomarker-led therapies are assisting it in growing its base in the rare disease environment, solidifying its position as a market leader in the orphan drug space.

Analysis by Distribution Channel :

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Stores
  • Others

Hospital pharmacies hold 48.2% of the market share. Hospital pharmacies hold the biggest market share. Hospital pharmacies are also essential in the dispensing of orphan drugs, especially because of the specialized nature and administration needs of these treatments. Most orphan drugs are applied in the treatment of complicated, life-threatening, or uncommon diseases that need close medical monitoring, hence the most suitable place for them to be dispensed is the hospital. These medications usually entail complex dosing regimens, intravenous delivery, or patient monitoring for side effects, all of which are best conducted in a hospital setting. Furthermore, hospitals commonly engage in post-marketing research and clinical trials, providing them with direct access to recently approved orphan therapies. Due to the limited availability and high price of orphan drugs, hospital pharmacies also collaborate closely with healthcare payers and drug manufacturers in ensuring proper inventory management as well as reimbursement coordination.

Regional Analysis:

  • North America
    • United States
    • Canada
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

In 2025, North America accounted for the largest market share of 35.5%. North America represents the largest segment, driven by strong regulatory support, technological advancements, and a rising focus on rare disease treatment. The United States, in particular, leads the region due to the well-established framework under the Orphan Drug Act, which provides incentives such as tax credits, market exclusivity, and expedited review processes. These provisions have encouraged pharmaceutical companies to invest in niche areas that previously lacked commercial viability. The increasing prevalence of rare diseases, estimated to affect over 30 million people in the US, is also contributing to growing demand for targeted therapies. Another leading trend is the convergence of precision medicine and genomic technologies in orphan drug development. With better diagnostic capabilities, more patients are being correctly diagnosed, resulting in improved treatment target and personalized treatments. Also, partnerships among biotech companies, academic institutions, and government agencies are driving innovation and accelerating research pipelines.

KEY REGIONAL TAKEAWAYS:

UNITED STATES ORPHAN DRUGS MARKET ANALYSIS

The United States hold 93.00% of the market share in North America. The United States experiences increasing orphan drug adoption due to growing investment in THE pharmaceutical sector, driving research into rare diseases. According to reports, in the US pharmaceutical industry, there were 25 private equity deals announced in Q3 2024, worth a total value of USD 2.3 Billion. Pharmaceutical companies allocate substantial resources to develop therapies targeting conditions with limited treatment options. Regulatory incentives, including expedited approvals and market exclusivity, encourage innovation. Growing collaborations between biotechnology firms and research institutions further accelerate drug development. Rising healthcare expenditures support the availability of orphan drugs, improving accessibility for patients. Expanding clinical trials enhance treatment options, addressing unmet medical needs. Public and private funding initiatives boost research efforts, fostering drug innovation. Advancements in drug formulation improve efficacy and patient outcomes. Increased awareness among healthcare providers leads to early diagnosis and intervention, optimizing treatment success, and thereby driving the market for orphan drugs.

ASIA PACIFIC ORPHAN DRUGS MARKET ANALYSIS

Asia-Pacific witnesses expanding orphan drug adoption due to the increasing prevalence of cancer, prompting pharmaceutical companies to develop specialized treatments. According to the National Cancer Registry Programme, the estimated number of incident cases of cancer in India for the year 2022 was found to be 14,61,427. Rising incidence of rare malignancies creates demand for novel therapies addressing unmet medical needs. Advancements in medical technology enhance drug discovery, leading to more effective treatment options. Favorable regulatory policies streamline approval processes, accelerating drug availability. Growing investments in oncology research foster innovation, promoting targeted therapies. Expanding healthcare infrastructure improves access to specialized treatments, supporting patient outcomes. Expanding clinical research collaborations facilitate new drug development, enhancing treatment efficacy. Increasing healthcare spending strengthens access to high-cost orphan drugs, ensuring affordability. Personalized medicine advancements align with the development of precision therapies, benefiting patients with rare cancers and augmenting the need for orphan drugs.

EUROPE ORPHAN DRUGS MARKET ANALYSIS

Europe is experiencing increasing orphan drug adoption due to growing research and development activities, propelling advancements in rare disease treatment. According to Eurostat, in 2023, the EU spent €381 Billion on research and development; R&D expenditure as a percentage of GDP stood at 2.22% in 2023, compared with 2.08% in 2013. Rising investment in drug discovery is facilitating novel therapeutic innovations. Expanding partnerships between biotech firms and academic institutions are accelerating clinical trials for orphan drugs. Enhanced funding in genetic research is enabling personalized medicine breakthroughs. Adoption of advanced biopharmaceutical technologies is improving drug efficacy and patient outcomes. Streamlined regulatory frameworks support faster orphan drug approvals. Moreover, the development of specialized research centers is expediting orphan drug discovery. Expanding healthcare innovation hubs are fostering new treatment methodologies. Support for translational research is enabling swift transition from laboratory discoveries to clinical applications.

LATIN AMERICA ORPHAN DRUGS MARKET ANALYSIS

Latin America observes expanding orphan drugs adoption due to growing online stores, offering greater accessibility to specialized treatments. The shift toward digital healthcare platforms enhances drug availability, allowing patients to access medications conveniently. Rising internet penetration supports e-commerce growth, driving online pharmaceutical sales. Streamlined distribution channels reduce barriers to obtaining orphan drugs, improving affordability. Digital pharmacies facilitate direct patient engagement, enhancing treatment adherence. Expanding telemedicine services complement online sales, promoting seamless healthcare access. Increasing digital literacy strengthens consumer confidence in online healthcare solutions.

MIDDLE EAST AND AFRICA ORPHAN DRUGS MARKET ANALYSIS

Middle East and Africa witness increasing orphan drugs adoption due to growing healthcare infrastructure, enhancing treatment accessibility for rare diseases. According to the Dubai Healthcare City Authority report, Dubai's healthcare sector saw rapid growth, with 4,482 private medical facilities and 55,208 licensed professionals by 2022, projected to expand further by 3-6% in facilities and 10-15% in professionals in 2023. Expanding medical facilities improve diagnosis and patient care, strengthening market penetration. Government investments in specialized healthcare services facilitate orphan drug availability. Advancements in hospital networks ensure efficient drug distribution, supporting patient needs. Regulatory developments streamline drug approvals, accelerating market entry. Rising medical research initiatives foster innovation, contributing to orphan drug development.

COMPETITIVE LANDSCAPE:

Market players in the orphan drugs space are increasingly making strategic partnerships and mergers and acquisitions (M&A) to improve their research pipelines and broaden their product offerings. Pharmaceutical and biotech firms are prioritizing novel drug development, especially in fields like gene therapy, immunotherapy, and rare oncology. A key trend is the increase in alliances between specialty biotech companies and large pharma companies that have more commercialization capabilities. Firms are also using regulatory incentives to speed up development and obtain market exclusivity. Many players are investing in new, high-tech innovation such as AI-powered drug discovery and precision medicine to make clinical trials more efficient, thereby driving the orphan drugs market demand. These activities demonstrate an innovation and competition-oriented environment towards fulfilling unmet medical requirements for rare diseases.

The report provides a comprehensive analysis of the competitive landscape in the orphan drugs market with detailed profiles of all major companies, including:

  • Alexion Pharmaceuticals Inc.
  • Amgen Inc.
  • AstraZeneca
  • Bayer AG
  • Daiichi Sankyo Company Limited
  • Genentech USA, Inc (F. Hoffmann-La Roche AG)
  • GSK plc
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis Pharmaceuticals Corporation
  • Pfizer Inc.
  • Sanofi S.A.
  • Takeda Pharmaceuticals U.S.A., Inc

KEY QUESTIONS ANSWERED IN THIS REPORT

1. How big is the orphan drugs market?

2. What is the future outlook of orphan drugs market?

3. What are the key factors driving the orphan drugs market?

4. Which region accounts for the largest orphan drugs market share?

5. Which are the leading companies in the global orphan drugs market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Orphan Drugs Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Drug Type

  • 6.1 Biological
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Non-Biological
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Disease Type

  • 7.1 Oncology
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Hematology
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Neurology
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Cardiovascular
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Others
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast

8 Market Breakup by Phase

  • 8.1 Phase I
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Phase II
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Phase III
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Phase IV
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9 Market Breakup by Top Selling Drugs

  • 9.1 Revlimid
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Rituxan
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Copaxone
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast
  • 9.4 Opdivo
    • 9.4.1 Market Trends
    • 9.4.2 Market Forecast
  • 9.5 Keytruda
    • 9.5.1 Market Trends
    • 9.5.2 Market Forecast
  • 9.6 Imbruvica
    • 9.6.1 Market Trends
    • 9.6.2 Market Forecast
  • 9.7 Avonex
    • 9.7.1 Market Trends
    • 9.7.2 Market Forecast
  • 9.8 Sensipar
    • 9.8.1 Market Trends
    • 9.8.2 Market Forecast
  • 9.9 Soliris
    • 9.9.1 Market Trends
    • 9.9.2 Market Forecast
  • 9.10 Others
    • 9.10.1 Market Trends
    • 9.10.2 Market Forecast

10 Market Breakup by Distribution Channel

  • 10.1 Hospital Pharmacies
    • 10.1.1 Market Trends
    • 10.1.2 Market Forecast
  • 10.2 Retail Pharmacies
    • 10.2.1 Market Trends
    • 10.2.2 Market Forecast
  • 10.3 Online Stores
    • 10.3.1 Market Trends
    • 10.3.2 Market Forecast
  • 10.4 Others
    • 10.4.1 Market Trends
    • 10.4.2 Market Forecast

11 Market Breakup by Region

  • 11.1 North America
    • 11.1.1 United States
      • 11.1.1.1 Market Trends
      • 11.1.1.2 Market Forecast
    • 11.1.2 Canada
      • 11.1.2.1 Market Trends
      • 11.1.2.2 Market Forecast
  • 11.2 Asia Pacific
    • 11.2.1 China
      • 11.2.1.1 Market Trends
      • 11.2.1.2 Market Forecast
    • 11.2.2 Japan
      • 11.2.2.1 Market Trends
      • 11.2.2.2 Market Forecast
    • 11.2.3 India
      • 11.2.3.1 Market Trends
      • 11.2.3.2 Market Forecast
    • 11.2.4 South Korea
      • 11.2.4.1 Market Trends
      • 11.2.4.2 Market Forecast
    • 11.2.5 Australia
      • 11.2.5.1 Market Trends
      • 11.2.5.2 Market Forecast
    • 11.2.6 Indonesia
      • 11.2.6.1 Market Trends
      • 11.2.6.2 Market Forecast
    • 11.2.7 Others
      • 11.2.7.1 Market Trends
      • 11.2.7.2 Market Forecast
  • 11.3 Europe
    • 11.3.1 Germany
      • 11.3.1.1 Market Trends
      • 11.3.1.2 Market Forecast
    • 11.3.2 France
      • 11.3.2.1 Market Trends
      • 11.3.2.2 Market Forecast
    • 11.3.3 United Kingdom
      • 11.3.3.1 Market Trends
      • 11.3.3.2 Market Forecast
    • 11.3.4 Italy
      • 11.3.4.1 Market Trends
      • 11.3.4.2 Market Forecast
    • 11.3.5 Spain
      • 11.3.5.1 Market Trends
      • 11.3.5.2 Market Forecast
    • 11.3.6 Russia
      • 11.3.6.1 Market Trends
      • 11.3.6.2 Market Forecast
    • 11.3.7 Others
      • 11.3.7.1 Market Trends
      • 11.3.7.2 Market Forecast
  • 11.4 Latin America
    • 11.4.1 Brazil
      • 11.4.1.1 Market Trends
      • 11.4.1.2 Market Forecast
    • 11.4.2 Mexico
      • 11.4.2.1 Market Trends
      • 11.4.2.2 Market Forecast
    • 11.4.3 Others
      • 11.4.3.1 Market Trends
      • 11.4.3.2 Market Forecast
  • 11.5 Middle East and Africa
    • 11.5.1 Market Trends
    • 11.5.2 Market Breakup by Country
    • 11.5.3 Market Forecast

12 SWOT Analysis

  • 12.1 Overview
  • 12.2 Strengths
  • 12.3 Weaknesses
  • 12.4 Opportunities
  • 12.5 Threats

13 Value Chain Analysis

14 Porters Five Forces Analysis

  • 14.1 Overview
  • 14.2 Bargaining Power of Buyers
  • 14.3 Bargaining Power of Suppliers
  • 14.4 Degree of Competition
  • 14.5 Threat of New Entrants
  • 14.6 Threat of Substitutes

15 Price Analysis

16 Competitive Landscape

  • 16.1 Market Structure
  • 16.2 Key Players
  • 16.3 Profiles of Key Players
    • 16.3.1 Alexion Pharmaceuticals Inc.
      • 16.3.1.1 Company Overview
      • 16.3.1.2 Product Portfolio
      • 16.3.1.3 Financials
      • 16.3.1.4 SWOT Analysis
    • 16.3.2 Amgen Inc.
      • 16.3.2.1 Company Overview
      • 16.3.2.2 Product Portfolio
      • 16.3.2.3 Financials
      • 16.3.2.4 SWOT Analysis
    • 16.3.3 AstraZeneca
      • 16.3.3.1 Company Overview
      • 16.3.3.2 Product Portfolio
      • 16.3.3.3 Financials
      • 16.3.3.4 SWOT Analysis
    • 16.3.4 Bayer AG
      • 16.3.4.1 Company Overview
      • 16.3.4.2 Product Portfolio
      • 16.3.4.3 Financials
      • 16.3.4.4 SWOT Analysis
    • 16.3.5 Daiichi Sankyo Company Limited
      • 16.3.5.1 Company Overview
      • 16.3.5.2 Product Portfolio
      • 16.3.5.3 Financials
      • 16.3.5.4 SWOT Analysis
    • 16.3.6 Genentech USA, Inc (F. Hoffmann-La Roche AG)
      • 16.3.6.1 Company Overview
      • 16.3.6.2 Product Portfolio
      • 16.3.6.3 SWOT Analysis
    • 16.3.7 GSK plc
      • 16.3.7.1 Company Overview
      • 16.3.7.2 Product Portfolio
      • 16.3.7.3 Financials
      • 16.3.7.4 SWOT Analysis
    • 16.3.8 Johnson & Johnson
      • 16.3.8.1 Company Overview
      • 16.3.8.2 Product Portfolio
      • 16.3.8.3 Financials
      • 16.3.8.4 SWOT Analysis
    • 16.3.9 Merck & Co., Inc.
      • 16.3.9.1 Company Overview
      • 16.3.9.2 Product Portfolio
      • 16.3.9.3 Financials
      • 16.3.9.4 SWOT Analysis
    • 16.3.10 Novartis Pharmaceuticals Corporation
      • 16.3.10.1 Company Overview
      • 16.3.10.2 Product Portfolio
      • 16.3.10.3 Financials
      • 16.3.10.4 SWOT Analysis
    • 16.3.11 Pfizer Inc.
      • 16.3.11.1 Company Overview
      • 16.3.11.2 Product Portfolio
      • 16.3.11.3 Financials
      • 16.3.11.4 SWOT Analysis
    • 16.3.12 Sanofi S.A.
      • 16.3.12.1 Company Overview
      • 16.3.12.2 Product Portfolio
      • 16.3.12.3 Financials
      • 16.3.12.4 SWOT Analysis
    • 16.3.13 Takeda Pharmaceuticals U.S.A., Inc
      • 16.3.13.1 Company Overview
      • 16.3.13.2 Product Portfolio
      • 16.3.13.3 Financials
      • 16.3.13.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Orphan Drugs Market: Major Drivers and Challenges
  • Figure 2: Global: Orphan Drugs Market: Sales Value (in Billion USD), 2020-2025
  • Figure 3: Global: Orphan Drugs Market: Breakup by Drug Type (in %), 2025
  • Figure 4: Global: Orphan Drugs Market: Breakup by Disease Type (in %), 2025
  • Figure 5: Global: Orphan Drugs Market: Breakup by Phase (in %), 2025
  • Figure 6: Global: Orphan Drugs Market: Breakup by Top Selling Drugs (in %), 2025
  • Figure 7: Global: Orphan Drugs Market: Breakup by Distribution Channel (in %), 2025
  • Figure 8: Global: Orphan Drugs Market: Breakup by Region (in %), 2025
  • Figure 9: Global: Orphan Drugs Market Forecast: Sales Value (in Billion USD), 2026-2034
  • Figure 10: Global: Orphan Drugs (Biological) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 11: Global: Orphan Drugs (Biological) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 12: Global: Orphan Drugs (Non-Biological) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 13: Global: Orphan Drugs (Non-Biological) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 14: Global: Orphan Drugs (Oncology) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 15: Global: Orphan Drugs (Oncology) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 16: Global: Orphan Drugs (Hematology) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 17: Global: Orphan Drugs (Hematology) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 18: Global: Orphan Drugs (Neurology) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 19: Global: Orphan Drugs (Neurology) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 20: Global: Orphan Drugs (Cardiovascular) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 21: Global: Orphan Drugs (Cardiovascular) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 22: Global: Orphan Drugs (Other Disease Types) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 23: Global: Orphan Drugs (Other Disease Types) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 24: Global: Orphan Drugs (Phase I) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 25: Global: Orphan Drugs (Phase I) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 26: Global: Orphan Drugs (Phase II) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 27: Global: Orphan Drugs (Phase II) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 28: Global: Orphan Drugs (Phase III) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 29: Global: Orphan Drugs (Phase III) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 30: Global: Orphan Drugs (Phase IV) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 31: Global: Orphan Drugs (Phase IV) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 32: Global: Orphan Drugs (Revlimid) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 33: Global: Orphan Drugs (Revlimid) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 34: Global: Orphan Drugs (Rituxan) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 35: Global: Orphan Drugs (Rituxan) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 36: Global: Orphan Drugs (Copaxone) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 37: Global: Orphan Drugs (Copaxone) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 38: Global: Orphan Drugs (Opdivo) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 39: Global: Orphan Drugs (Opdivo) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 40: Global: Orphan Drugs (Keytruda) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 41: Global: Orphan Drugs (Keytruda) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 42: Global: Orphan Drugs (Imbruvica) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 43: Global: Orphan Drugs (Imbruvica) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 44: Global: Orphan Drugs (Avonex) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 45: Global: Orphan Drugs (Avonex) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 46: Global: Orphan Drugs (Sensipar) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 47: Global: Orphan Drugs (Sensipar) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 48: Global: Orphan Drugs (Soliris) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 49: Global: Orphan Drugs (Soliris) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 50: Global: Orphan Drugs (Other Drugs) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 51: Global: Orphan Drugs (Other Drugs) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 52: Global: Orphan Drugs (Hospital Pharmacies) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 53: Global: Orphan Drugs (Hospital Pharmacies) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 54: Global: Orphan Drugs (Retail Pharmacies) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 55: Global: Orphan Drugs (Retail Pharmacies) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 56: Global: Orphan Drugs (Online Stores) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 57: Global: Orphan Drugs (Online Stores) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 58: Global: Orphan Drugs (Other Distribution Channels) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 59: Global: Orphan Drugs (Other Distribution Channels) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 60: North America: Orphan Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 61: North America: Orphan Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 62: United States: Orphan Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 63: United States: Orphan Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 64: Canada: Orphan Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 65: Canada: Orphan Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 66: Asia Pacific: Orphan Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 67: Asia Pacific: Orphan Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 68: China: Orphan Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 69: China: Orphan Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 70: Japan: Orphan Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 71: Japan: Orphan Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 72: India: Orphan Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 73: India: Orphan Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 74: South Korea: Orphan Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 75: South Korea: Orphan Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 76: Australia: Orphan Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 77: Australia: Orphan Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 78: Indonesia: Orphan Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 79: Indonesia: Orphan Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 80: Others: Orphan Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 81: Others: Orphan Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 82: Europe: Orphan Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 83: Europe: Orphan Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 84: Germany: Orphan Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 85: Germany: Orphan Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 86: France: Orphan Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 87: France: Orphan Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 88: United Kingdom: Orphan Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 89: United Kingdom: Orphan Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 90: Italy: Orphan Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 91: Italy: Orphan Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 92: Spain: Orphan Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 93: Spain: Orphan Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 94: Russia: Orphan Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 95: Russia: Orphan Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 96: Others: Orphan Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 97: Others: Orphan Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 98: Latin America: Orphan Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 99: Latin America: Orphan Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 100: Brazil: Orphan Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 101: Brazil: Orphan Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 102: Mexico: Orphan Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 103: Mexico: Orphan Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 104: Others: Orphan Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 105: Others: Orphan Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 106: Middle East and Africa: Orphan Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 107: Middle East and Africa: Orphan Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 108: Global: Orphan Drugs Industry: SWOT Analysis
  • Figure 109: Global: Orphan Drugs Industry: Value Chain Analysis
  • Figure 110: Global: Orphan Drugs Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Orphan Drugs Market: Key Industry Highlights, 2025 and 2034
  • Table 2: Global: Orphan Drugs Market Forecast: Breakup by Drug Type (in Million USD), 2026-2034
  • Table 3: Global: Orphan Drugs Market Forecast: Breakup by Disease Type (in Million USD), 2026-2034
  • Table 4: Global: Orphan Drugs Market Forecast: Breakup by Phase (in Million USD), 2026-2034
  • Table 5: Global: Orphan Drugs Market Forecast: Breakup by Top Selling Drugs (in Million USD), 2026-2034
  • Table 6: Global: Orphan Drugs Market Forecast: Breakup by Distribution Channel (in Million USD), 2026-2034
  • Table 7: Global: Orphan Drugs Market Forecast: Breakup by Region (in Million USD), 2026-2034
  • Table 8: Global: Orphan Drugs Market Structure
  • Table 9: Global: Orphan Drugs Market: Key Players